Hemant Surgical Industries Limited

Hemant Surgical Industries Ltd. (HSIL) - New SME IPO with Market cap of Rs. 94 crores.

It is in the business of manufacturing/importing/assembling and marketing a comprehensive portfolio of medical equipment and disposables.

Its product offerings cover a wide spectrum of equipment and disposables required for (i) Renal Care, (ii) cardiovascular disease (iii) respiratory disease, (iv) Critical Care and Radiology and (v) Surgical disposables.

It is a new SME IPO which is yet to list on the exchanges.

Raising 25cr -All fresh issue (No OFS)

Post IPO - Promoter holding at 74%

Impressive Last 3 year performance -
Debt down from 15cr to 7cr

Revenue up from 60cr to 112cr

PAT up from 1cr to 8cr
PAT margin from 1% to 7%

IPO valuation - very reasonable at 12x PE multiple.

ROCE and ROE at 32% and 38% respectively

Found one old credit rating report which gives some information on the company- https://www.icra.in/Rationale/ShowRationaleReport?Id=112211

At IPO price - it will be at Rs. 94 crores of Market cap

I am more attracted with the numbers for last 3 years and ROCE of 32%

Please add further if anyone have further information.

6 Likes

As of 24th August 2023:

Hemant Surgical Industries Ltd. It is a 262 Cr market cap company as of today and quoting at a PE of 34 and price to sales of 2.4

Company is profitable with positive cash flow from last 3 years. As name indicate it is in business of importing and manufacturing medical equipments. Incorporated in 1989 and currently run by second generation entrepreneur. They have technical collaboration with JMS (Japan) and initially importing the equipments and selling in India :india: but now they are manufacturing the products and selling and having benefitted by make in India and PLI scheme. Future is looking great and company having potential to grow further.
Opportunity is looking like a small fish in the big pond.
Currently 51% of revenue is coming from manufacturing going forward this percentage will increase further and margin will also improve in this process.

Some key financials:
ROCE: 45%
ROE: 41%
PEG ratio: 0.65

Last FY sales: 109 Cr
Net Profit: 8 Cr
OPM:10%

The stock is listed in BSE SME platform and trading in lots, lot size: 1600

I basically did read this company as part of understanding the Medical device segment in India. There are 100% FDI, PLI and Government intent to get medical devices manufactured in India but as of now India produces low value commodity products in India and the rest are distributed by importing.

My understanding of the company is as follow

  • Company is the distributor for the foreign products - new and refurbished.
  • They do few assemblies in India but no value-added manufacturing.

I did not dive deep into the company as I could not find any attractiveness in its business - they are one among the distributors and products they sell do have a lot of players in the market.

In case you are checking in more detail do check if they are planning to enter move value added manufacturing in coming years.

1 Like

Has anyone analysed Saakshi medtech…latest IPO SME… seems like they have promising future in medical devices and electronic panels

1 Like

Have done some research, please read and add.

Wiring harness is captive only, And medical devices they haven’t really started much in it… it’s mostly panels for xray machine i believe… Majority of the business currently is for panels.

Sharing some findings befor i invested in the IPO:

Jo MTAR - Bloom Energy ka relation hai …waise hi kuch

Sakshi - General Electric ka lag raha hai.

Founder is also an ex employee of GE. More you read about this company more interesting it seems.

21 years of working experience.
Products division:

Healthcare
Control Panel
Locomotive
Wire Harness

Major ClientS:
GE - plans to divest non-core business and focus more on industrial business - like aviation, healthcare, and renewable energy.,

Baker Hughes ( formerly a GE company) - into oilfield exploration and drilling (growth prospects increases with rising crude,

Kirloskar,

Wipro+GE JV - specializes in medical imaging and diagnostics - among prominent players who are exporting medical devices.

-The medical devices market in India was estimated to be US$ 12 billion in 2020, but it has the potential to reach US$ 50 billion by 2025.
-Diagnostic imaging is expected to expand at a CAGR of 13.5% between 2020-25.
-The sector includes large multinationals and small to mid-sized companies, offering opportunities for domestic players to penetrate global markets.
-Government initiatives, research and development (R&D) focus, and 100% FDI are supporting the growth of the medical devices sector.

Wabtec (Locomotive) - Wabtec operates under two financial reporting segments: Freight segment, which includes Equipment, Components, Services and Digital Intelligence; and the Transit segment, which includes Equipment and Aftermarket Services

All sectors they are working in have huge potential. Very interesting company.

3 Likes

Is anyone aware or have any details about their service segment? They’ve mentioned key success in their dialysis center setup/mgmt but does anyone know the quantum (revenue) & scope of their service segment as whole as they are offering turnkey setups for various applications

1 Like

Hemant Surgical Industries Ltd. (HSIL) - A More Comprehensive Take

Introduction

  • Founded in 1989, a CDSCO compliant co. with 3+ decades of experience in manufacturing/importing/assembly & marketing medical equipment & disposables.
  • Products cater to (i) Renal care, (ii) cardiovascular, (iii) respiratory, (iv) critical care & radiology and (v) surgical disposables.
  • 1 ISO certified manuf. unit & 2 assembly units.
  • Widespread customer base in India & 10+ countries

Exclusive distribution agreements with 8+ MNC cos: (Agreements usually for period of 3-5yrs validity)

A deep dive into collaboration w/JMS Co, Japan

  • HSIL began its operations by forming a technical collaboration with JMS to import and market its Meditape (for wound care) in India.
    • Used to import jumbo rolls and then cut/process it before selling
  • As JMS gained more confidence over HSIL, they formed another collaboration b/w their subsidiary JMS Singapore for importing intravenous infusion set as well.
    • JMS IV sets are given preference in hospitals due to its accuracy (and in general IV sets are the 1st thing that a patient needs in a hospital)
  • Later due to increase in technology transfer & HSIL’s move towards more value addition products – installed a plant and since FY’22 have been manufacturing ~60% of JMS products in India
    • This led to cost competitiveness, increased volumes & profitability
  • JMS products contributed ~50% to the revenues of HSIL in FY23 and the key product – Meditape alone accounted for 33% of the total revenues in FY’23
  • Current status: Ordered machineries might take ~6mo-1yr for setup/validation from partners to move towards 100% localization of the products

Other Collaborations

  • Sole agent of SWS Hemodialysis China to sale & maintain SWS-4000A machines in West India on exclusive basis.
  • Mediply: for supply of renal care equipment, medical devices & consumables for marketing in Philippines
  • Zoncare Bio-medical Electronics : catering needs of radiology; import & assembly of critical care products viz. ultrasound machine

Apart from agreements w/MNCs, HSIL has created 6 brands (viz. Aero+, Joylife, Safecath, Comfort, Citro-H & Diaclean) of their own under which they sell various products

Products & Services

Products

  • JMS Products: Meditape, Infusion set, Transfusion set & Scalp vein set
  • Renal Care: (i) Hemodialysis machine (imported from SWS & refurbished machines imported from France & Aus), (ii) Dialysis Solution & (iii) Dialyzer (sold under brand: Dora, JMS & Aero)
  • Cardiovascular: (i) ECG machine (imported) and (ii) ECG electrode (sold under brand Aero+)
    • Got approval for 50+ cardiac products, intend to manuf. and launch in Indian & Global markets
  • Respiratory: Nebulizer (Aero+)
  • Critical care & Radiology: Paramonitors, Ultrasound machines (imported), Ventilator (Aero)

Services

  • Turnkey Dialysis Setup & Management
    • Currently operate & manage 5 of own dialysis centers; set up & managed 100+ dialysis centers worldwide
  • Imaging & Diagnostic Center Setup
  • Modular ICU/MOT Setup
  • Oncology Labs & Treatment Centers Setup
  • Blood Bank/Dental Clinic Setup

V.successful in turnkey operations for renal care in Africa for creating dialysis centers. Installed more than 200+ turnkey projects (in Philippines & African countries)

This year looking for few turnkey projects which are in pipeline along with govt tenders also in pipeline

Manufactures the above products, rest are imported and assembled; Overall capacity utilization is quite low meaning there is a lot of potential to scale up.

As seen, co. is gradually increasing the scale of manufacturing in order to improve profitability & become more self-sufficient.

Promoter Background

  • Promoter has 3+ decades of experience in the medical equipment industry
  • Group cos. same line of biz: Ikigai Services, Diaso Diagnostics LLP, Ikigai Medequipments (same promoter) – conflict in operations.
  • Hanskumar & Kaushik Shah were disqualified from directorship from Nov’16 to Oct’21 (did not file financial statements for 3 consecutive yrs in previous directorship at Millenium Industries pvt ltd)

Other Key Pointers

  • HSIL has a moderate scale of operations with relatively lower value addition which limits its margins, going forward it needs to move towards more value-additive products to improve margins.
  • Sales strategy: PAN India digital marketing to create awareness of products. 35-40+ marketing reps & 300+ dealers/distributors wide network.
    • Preference to sales via dealer strategy rather than direct to institutions due to maintaining cash flow cycle and convenience
  • Key customers majorly include a network of ~80 dealers/distributors and hospitals, diagnostic centres & individual doctors. Top 10 customers: 41% of total revenue (FY’23)
  • Top 10 suppliers: 80% (FY23), 77% (FY22) & 84% (FY21)
  • Imports purchases: accounted for 76% (Fy23), 75% (FY22) & 69% (FY23) of total purchases
  • Revenue mix: JMS products (40%), Renal Care (20%), Exports (20%), Own brands & other segments (20%)
  • Majorly exporting to Africa & Phillipines
  • Further expansion: cardiac products registered, critical care & ophthalmology (signed contracts w/reputed german cos. to market their products)

Financial Snapshot

  • FY’22 sales higher due to increase in demand of critical care products post-covid & also increased volumes of JMS products sold due to increased in-house manufacturing
  • Margins:
    • Cos. margins largely remained in the range of 4–5% earlier due to relatively limited value addition in the nature of its operations and limited economies of scale owing to moderate scale of operations.
    • Improvement in margins in the past 2 yrs driven by driven by widening of the product profile as well as increasing revenue contribution from manufacturing sales. Major component being – ~60% of JMS products were being manufactured by HSIL in India & also started to focus on govt. tenders.
  • Good return ratios: 7-yr avg. ROE/ROCE around 24%
  • Actively reduced its borrowings and is a net cash company since last 2 yrs.

AR’24 Update:

Interviews: https://www.youtube.com/watch?v=X_4FUmEst9w (better & recent one)
https://www.youtube.com/watch?v=2Q1OGcq0YsQ

Disc: Not Invested; tracking

3 Likes

Hello Sir,

If you don’t mine sharing source, reports and some more details on “Medical Devices Sector as a whole.” Also, if you can share your view on how is the outlook for Medical Devices based on what you have researched so far.

Would be very helpful. I am trying to do sector research on same.

Regards,
Mukul

Please note following is my notes from past study, the primary source is DRHP industry section and followed by search in general.

Indian Medical Devices Industry

As of 2020, the medical devices market is estimated to be at US$ 12 billion in India. The Indian market for medical equipment is predicted to increase to US$ 50 billion by 2025.

  • Between 2020-25, diagnostic imaging is likely to expand at a CAGR of 13.5%

The Indian medical devices sector is broadly classified into 5 segments – Electronics equipment, Surgical instruments, Implants, IVD (In-vitro Diagnostic) devices/reagents and Consumables & Disposables.

India has a 75-80% import dependency on medical devices, with exports of US$ 2.53 billion in FY21, which is expected to increase at a CAGR of 41% to reach US$ 10 billion by 2025. Domestic manufacturing is largely focused on low-cost- high volume segments (like Consumables and Disposables)

  • 100% FDI is allowed in the medical devices sector in India. Categories such as equipment and instruments, consumables, and implants attract the most FDI.
  • PLI scheme for domestic manufacturing of medical devices, with a total outlay of funds worth Rs. 3,420 crores (US$ 468.78 million) for the period FY21-28.
  • Total committed investment of ~Rs. 729.63 crore (US$ 100.01 million) by the companies Siemens Healthcare Private Limited, Allengers Medical Systems Limited (AMSL), Allengers OEM Private Limited (AOPL), Wipro GE Healthcare Private Limited, Nipro India Corporation Private Limited, Sahajanand Medical Technologies Private Limited, Innvolution Healthcare Private Limited, and Integris Health Private Limited, and generate ~2,304 jobs.
    • Most of these players are doing research with collaboration in IIT/NIIT and another top university in India.
  • Introduction of Medical Parks - Noida, Himachal Pradesh, and UP has proposed to set up parks that will bring in an investment of ~10000 crores.
  • Indian Council of Medical Research (ICMR) collaborated with the Indian Institutes of Technology (IITs) to establish ‘ICMR at IITs’ by setting up Centres of Excellence (CoE) for Make-in-India product development and commercialization in the medical devices and diagnostics space
    • The CoEs are a major initiative that will help to improve the health of the Indian population. They will make high-quality medical devices and diagnostic tools more affordable and accessible to patients and healthcare providers across the country. This will help to improve the quality of care and reduce the cost of healthcare in India.

Policy Support and Government Initiatives

The government announced Rs. 64,180 crores (US$ 8.80 billion) outlay for the healthcare sector over six years in the Union Budget 2021-22 to strengthen the existing ‘National Health Mission’ by developing capacities of primary, secondary and tertiary care, healthcare systems, and institutions for detection and cure of new & emerging diseases.

  • The Government of India approved the continuation of ‘National Health Mission’ with a budget of Rs. 37,000 crore (US$ 4.85 billion) under the Union Budget 2022-23.
  • The Indian government is planning to introduce a credit incentive program worth Rs. 500 billion (US$ 6.8 billion) to boost the country’s healthcare infrastructure.
  • Pradhan Mantri Swasthya Suraksha Yojana - In the Union Budget 2022-23, Rs. 10,000 crore (US$ 1.31 billion) was allocated to the scheme. The Government of India will use this money to boost the medical education infrastructure of the country and set up AIIMS across the country.
  • PM Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) - In the Union Budget 2022-23, Rs. 5,156 crore (US$ 675.72 million) was allocated to the newly announced PM-ABHIM to strengthen India’s health infrastructure and improve the country’s primary, secondary and tertiary care services.

The Union Cabinet approved setting up of the National Nutrition Mission (NNM) to monitor, supervise, fix targets and guide nutrition-related interventions across ministries. Over 100 million people are expected to be benefited by this program – the program will cover all states and districts.

  • In the Union Budget 2021-22, the government announced its plans to launch ‘Mission Poshan 2.0’ to merge ‘Supplementary Nutrition Programme’ with ‘Poshan Abhiyan’ (Nutrition Mission)

The Ministry of Health and Family Welfare’s eSanjeevani telemedicine consultation service crossed 3 crore teleconsultations as on March 25, 2022.

Ayushman Bharat - Ayushman Bharat-Health and Wellness Centres, Ayushman Bharat Health Account and Ayushman Bharat Digital Mission.****

In BioAsia 2021, key stakeholders in the panel discussion on medical technologies stated that India would become self-sufficient in domestic medical device manufacturing by 2025-26

Few Companies which are listed or come with IPO proposal

Poly Medicure Ltd. (POLYMED) is a leading player in the organized medical disposable devices market with strong brand positioning due to high-quality products used in infusion therapy, blood management, surgery, dialysis, and other segments. POLYMER is the largest exporter of medical devices from India. POLYMED is among the top three IV Cannula manufacturers in the world and the first indigenous dialyzer manufacturer

  • Company extremely export-oriented company

Hemant Surgical Industries Limited - manufacture, import, assemble and market a comprehensive portfolio of medical equipment and disposables. Our product offerings cover a wide spectrum of equipment and disposables required for (i) Renal Care, (ii) Cardiovascular Disease (iii) Respiratory Disease, (iv) Critical Care and Radiology, and (v) Surgical disposables.

  • It acts as a distributor for some of the international player few things they assemble in India but no much value-added manufacturing happen within the company.

Opto Circuits offers a wide range of medical devices, including cardiac monitoring systems, patient monitors, infusion pumps, and surgical instruments. The company’s products are used in hospitals, clinics, and other healthcare settings.

  • Recently time company facing an extreme debt burden and stiff computation from it peers. This was the darling of the market but the company could not handle debt, This is one my biggest mistakes in my investment journey. You can call Suzlone of Medical Device.

There is limited called players in India if they have they are not listed in the market. This sector will enjoy the India health infra-building initiative. I need to find a way how to study the trend change in the sector which could impact the hospital or diagnostic industry for health service.

2 Likes

Very helpful sir. Thanks for the information!!

1 Like